Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Introgen makes appointment to board

This article was originally published in Scrip

Executive Summary

Introgen Therapeutics, a US biopharmaceutical company focused on the discovery, development and commercialisation of targeted molecular therapies for cancer and other diseases, has elected Dr James Rothman to its board of directors. In September, Dr Rothman, who is renowned for discovering the molecular machinery responsible for transfer of materials among compartments within cells, will relocate his laboratory from Columbia University to Yale University, where he will serve as the Wallace professor of biomedical sciences, chairman of the department of cell biology and founder of the Yale University Center for High-Throughput Cell Biology.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC006133

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel